TB-500 clinical trials: what the actual research record shows

Last updated 2026-07-25

Have there been any human clinical trials on TB-500?

No. As of this writing, there is no published record of a completed, peer-reviewed human clinical trial testing TB-500 for injury repair, tendon healing, or any other therapeutic claim. Search PubMed and you find something different: a run of analytical chemistry papers built to detect TB-500 in urine, plasma, and blood for anti-doping purposes, plus a handful of 2026 orthopaedic review articles that discuss peptide therapies as a category. That distinction matters more than most sourcing pages let on. A 2026 primer in The American Journal of Sports Medicine walks orthopaedic and sports medicine physicians through injectable peptide therapy as a class of emerging treatments ^[1]. A companion 2026 review in the Journal of the American Academy of Orthopaedic Surgeons' Global Research & Reviews covers therapeutic peptides in orthopaedics generally, flagging applications, challenges, and open questions ^[2]. Neither of these is a trial. They're reviews written because clinicians keep getting asked about these compounds and the primary trial data doesn't exist yet. A third 2026 paper, in Sports Medicine (Auckland), specifically examines safety and efficacy questions across both approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[3]. That's the closest thing to a trial-adjacent evidence synthesis in the current literature, and it's a review of existing safety and efficacy signals, not a new controlled trial of TB-500 in humans. If a website tells you TB-500 has passed clinical trials for tendon repair or muscle injury, that claim is not supported by anything currently indexed in PubMed. Ask for the specific trial registration number (a NCT identifier from ClinicalTrials.gov) before you believe it. For a plain look at the proposed mechanism behind these claims, see our companion piece on what does TB-500 actually do. For the practical dosing and pairing questions this piece sets aside, see our guide on TB-500 dosing protocols and our breakdown of the BPC-157 and TB-500 stack.

What is TB-500, and how is it different from thymosin beta-4?

Thymosin beta-4 (Tβ4) is a 43-amino-acid protein your body makes naturally. It's involved in cell migration, actin regulation, and wound healing processes that researchers have studied for decades. TB-500 is not the same molecule. TB-500 is typically a shorter synthetic peptide fragment, often described as covering the actin-binding region of Tβ4, sometimes further modified (for example, N-terminal acetylated versions). A 2012 paper in Drug Testing and Analysis specifically synthesized and characterized the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, because analytical chemists needed a reference standard to even confirm what commercial "TB-500" products actually contained ^[4]. That paper exists because the identity of TB-500 as sold was itself an open scientific question worth resolving with lab synthesis. This is the single most common conflation in TB-500 marketing copy: treating decades of native Tβ4 research as if it were TB-500 research. They share ancestry. They are not interchangeable in a citation. If a source cites a 1990s or 2000s wound-healing study on thymosin beta-4 and calls it "TB-500 evidence," read that claim skeptically. For a broader look at what the fragment is thought to do mechanistically, see what does TB-500 actually do, which covers the dosing and pairing questions this piece deliberately sets aside.

What does the preclinical research on TB-500 actually show?

The strongest mechanistic data point currently indexed is a 2024 paper in the Journal of Chromatography B that did two things at once: it developed a method to simultaneously quantify TB-500 and its metabolites using UHPLC-Q-Exactive Orbitrap mass spectrometry in in-vitro experiments and in rats, and it screened the resulting fragments for wound healing activity in vitro ^[5]. This is genuinely useful preclinical work. It tells researchers how TB-500 breaks down metabolically in a living rat system and gives an in-vitro read on whether the breakdown products retain any wound-healing signal. But it is exactly what its title says: an in-vitro and rat pharmacokinetics and metabolite-screening study, not a human clinical trial, and not evidence of a specific healing outcome in a human tendon, ligament, or muscle injury. A separate line of thymosin-related peptide research shows up in a 2026 Frontiers in Aging paper on therapeutic peptides in gerontology, which discusses mechanisms and applications for healthy aging broadly ^[6]. Again, useful context on the peptide-therapeutics landscape, not a TB-500-specific human trial. So the honest summary: TB-500 has real preclinical characterization (synthesis, metabolite ID, in-vitro wound assays, rat PK) but zero completed human efficacy trials in the indexed literature as of now. Anyone claiming otherwise owes you a specific citation.

Why does most of the TB-500 literature look like anti-doping chemistry, not medicine?

Because that's who has been paying to study it. Look at the actual publication pattern: the majority of TB-500-specific papers in PubMed come out of doping-control and forensic analytical chemistry labs, not orthopaedic clinical research groups. A 2012 paper in the Journal of Chromatography A developed a liquid chromatography-mass spectrometry method to detect TB-500 specifically in equine urine and plasma ^[7], because horse racing regulators needed to catch it. A 2013 paper in Analytical and Bioanalytical Chemistry extended doping-control detection to seven bioactive peptides in horse plasma, TB-500 among them ^[8]. A 2017 paper in Analytical Biochemistry studied adsorption effects for doping-relevant peptides including insulin lispro, Synacthen, TB-500, and GHRP-5, because peptides can stick to tubing and lab plastics in ways that mess up detection assays ^[9]. Human anti-doping labs have built out a comparable toolkit. A 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis reviewed analytical approaches for detecting emerging therapeutics and non-approved drugs, TB-500 included, in human doping controls ^[10]. A 2014 review in Expert Review of Proteomics covers detection of peptidic drugs and drug candidates in sports doping broadly ^[11]. A 2015 paper in the Journal of Peptide Science built in-vitro models for metabolic studies of small peptide hormones specifically for sport drug testing ^[12]. A 2016 paper in the Journal of Separation Science simplified urine screening for peptides under 2 kDa using direct injection LC and ion mobility mass spec ^[13]. Another 2016 paper, in the Journal of Proteomics, compared in-vitro model systems (proteolytic enzymes, serum, liver and kidney microsomes, liver S9 fraction) for metabolizing synthetic doping peptides ^[14]. A 2016 Drug Testing and Analysis paper worked out solid-phase extraction methods for small bioactive peptides from human urine on cartridges and 96-well plates ^[15]. That is eight-plus papers built entirely around catching TB-500 in a drug test, versus essentially zero papers built around proving it heals a human injury. That ratio tells you something about where the real institutional attention and funding has gone.

Is TB-500 banned in sports? What does WADA say?

Yes. Thymosin beta-4 and its derivative fragments, including TB-500, fall under WADA's prohibited list categories for peptides and growth factors affecting tissue repair. The dense anti-doping detection literature cited above exists precisely because sports federations and racing regulators treat TB-500 as a substance worth testing for, in both humans and horses ^{[7][8][9][10][11][12][13][14][15]}. If you are a tested athlete at any level where WADA code applies, using TB-500 carries real sanction risk regardless of what any preclinical rat data shows about wound healing. Check the current WADA Prohibited List directly before assuming any peptide is fine because it's not FDA-approved or because a vendor calls it "research use only." Research-use labeling does not exempt an athlete from anti-doping rules.

Is TB-500 FDA-approved, and can you buy it as a standalone product?

No, and no. TB-500 has no FDA-approved drug application. You can confirm this yourself by searching Drugs@FDA, the FDA's official approved drug products database, for any TB-500 listing ^[16]. There isn't one. TB-500 also is not on either of FDA's compounding bulk drug substance lists: not the 503A Bulks List under 21 CFR 216.23, which governs bulk substances traditional compounding pharmacies can use ^[17], and not the 503B Bulks List under 21 CFR 216.24, which governs outsourcing facilities ^[18]. FDA maintains a nomination list of bulk drug substances proposed for 503A compounding use, and reviewing that list is the right way to check current status rather than trusting a seller's claim ^[19]. What this means practically: there is no legitimate standalone TB-500 product for sale. Where TB-500 shows up through a licensed provider pathway, it is dispensed as part of a compounded BPC-157/TB-500 blend prepared by a pharmacy under 21 U.S.C. 353a, the statute governing pharmacy compounding ^[20], not as an isolated, FDA-approved single-ingredient drug. Anyone selling you a bottle labeled simply "TB-500" for injection into a human body is operating outside that framework, and you should treat the product's identity, purity, and dosing claims with real skepticism given how thin the standalone-product oversight is. Our guide to how the BPC-157/TB-500 compounded blend actually works covers what a licensed pathway looks like in practice.

What would a real clinical trial on TB-500 need to look like?

A trial worth citing needs a registration number, a control arm, a defined injury population, and a published outcome, not a testimonial. Here's the bar that hasn't been cleared yet: - Registration on ClinicalTrials.gov or an equivalent international registry, with a stated primary endpoint (grip strength recovery, imaging-confirmed tendon healing, time to return to play) decided before the trial started.

• A control or comparator group, ideally placebo-controlled and blinded, since musculoskeletal injuries have famously high placebo and natural-recovery rates that make uncontrolled case series unreliable.
• Human subjects with a diagnosed injury (Achilles tendinopathy, rotator cuff tear, muscle strain), not healthy volunteers or animal models.
• Peer-reviewed publication of the actual result, not a press release or a company blog post summarizing "promising early data."
• Dosing and administration details specific enough that another lab could replicate the protocol. None of the papers in the current TB-500 literature clear this bar. The closest adjacent work is the 2026 Sports Medicine review synthesizing safety and efficacy signals across approved and unapproved peptide therapies for musculoskeletal injury and athletic performance ^[3], and even that is a review of existing (largely non-TB-500-specific, or preclinical) evidence rather than a new trial. If you want a walkthrough of the doses researchers actually use in the preclinical literature, that's in our TB-500 dosing protocols piece.

How does the TB-500 evidence record compare to BPC-157?

Both peptides sit in roughly the same evidence category: strong preclinical and mechanistic interest, no completed human efficacy trials, and a compounding-only legal pathway in the US. Neither is on FDA's 503A or 503B bulks lists ^[17][18], and neither has a Drugs@FDA approval record ^[16]. Where they differ: BPC-157 has a larger and older animal-study base specifically around gut, tendon, and ligament healing models, while TB-500's most rigorous recent paper is the 2024 metabolite-quantification and in-vitro wound-healing screen in rats ^[5]. TB-500 also has the deeper anti-doping detection literature of the two, likely because its structural similarity to native Tβ4 made it an earlier target for equine and human doping labs ^[7][8][9].

This is why sourcing pages that treat BPC-157 and TB-500 as a package deal aren't wrong about the pairing being common in practice. They are wrong if they imply either one has cleared human trials independently. If you want the mechanism-level explanation for why these two get paired so often, that's covered in what does TB-500 actually do and in our dedicated BPC-157 and TB-500 stack guide.

Why is TB-500 sold as a BPC-157/TB-500 blend instead of on its own?

Because there's no standalone TB-500 SKU available through the legitimate provider-reviewed pathway. Where these peptides reach patients through a licensed medical route in the US, it's via 503A or 503B compounding pharmacies operating under 21 U.S.C. 353a ^[20], and in current practice that pathway offers TB-500 combined with BPC-157 in a single compounded preparation, not TB-500 by itself. TB-500 Co works within that reality: readers are pointed toward a provider-reviewed process where a clinician evaluates the request and, if appropriate, a compounding pharmacy partner fulfills a BPC-157/TB-500 blend. Nobody should expect to buy isolated TB-500 through a legitimate channel, because that product doesn't meaningfully exist in the current US regulatory landscape. If a seller offers you a standalone TB-500 vial with no clinician involved, that's a signal to ask hard questions about sourcing, purity testing, and legal status before anything gets near a needle. See our BPC-157 and TB-500 stack guide for how that compounded pathway is structured in practice.

What should you actually take away from the current evidence?

Treat every TB-500 claim online as sitting in one of three honest buckets: analytical chemistry (real, well-established, built for drug testing), preclinical animal/in-vitro work (real but limited, one solid 2024 rat and in-vitro paper ^[5]), or human efficacy claims (currently unsupported by any published trial). The 2026 clinical review literature ^[1][2][3] shows orthopaedic and sports medicine is actively working through how to think about this whole peptide category, which is a sign the field takes the question seriously, not a sign the trials exist yet. If you're weighing whether to use TB-500 for an injury, the responsible framing is: mechanistically plausible based on rodent and in-vitro data, legally available only through compounded blends via a licensed provider, banned for tested athletes under WADA rules, and unproven in humans by the standard a peer-reviewed clinical trial would require. For more on the proposed mechanism itself, read what does TB-500 actually do, and for the practical dosing questions that follow from this evidence record, see our TB-500 dosing protocols guide.

Frequently asked questions

Are there any completed human clinical trials on TB-500?

No. As of this writing, PubMed has no published record of a completed, controlled human clinical trial testing TB-500 for injury repair or any therapeutic outcome. The literature that exists is preclinical (rat and in-vitro studies) and analytical chemistry work built for anti-doping detection, not clinical efficacy trials.

Is TB-500 the same thing as thymosin beta-4?

No. Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein. TB-500 is a synthetic fragment associated with part of that protein, sometimes further modified, and its identity as sold commercially was specifically studied and characterized in a 2012 Drug Testing and Analysis paper because the two are not interchangeable ^[4].

Is TB-500 approved by the FDA?

No. A search of Drugs@FDA, the FDA's approved drug products database, shows no TB-500 listing. TB-500 also does not appear on FDA's 503A or 503B bulk drug substance lists under 21 CFR 216.23 and 216.24, which govern what compounding pharmacies can legally use.

Can you legally buy TB-500 by itself?

Not through a legitimate provider pathway. There is no standalone TB-500 product available legally in the US compounding system. Where it's dispensed through a licensed provider and compounding pharmacy, it comes as part of a BPC-157/TB-500 blend under 21 U.S.C. 353a, not as an isolated TB-500 product.

Is TB-500 banned by WADA for athletes?

Yes. TB-500 falls under WADA's prohibited categories for peptides affecting tissue repair, and the extensive anti-doping detection literature built for both equine and human testing exists specifically because sports regulators treat it as a substance to screen for. Tested athletes face sanction risk regardless of preclinical data on wound healing.

What does the 2024 TB-500 metabolite study actually show?

A 2024 paper in the Journal of Chromatography B developed a mass spectrometry method to simultaneously quantify TB-500 and its metabolites in vitro and in rats, then screened the resulting fragments for wound-healing activity in vitro. It's a metabolism and preclinical screening study, not a human efficacy trial, but it's currently the most detailed mechanistic TB-500 paper available.

Why is most TB-500 research about drug testing instead of medicine?

Because the funding and institutional interest has concentrated in anti-doping and forensic chemistry, not clinical orthopaedics. At least eight indexed papers from 2012 to 2017 focus on detecting TB-500 in human or equine urine, plasma, or blood for doping control, versus essentially no completed clinical efficacy trials in humans.

Does BPC-157 have better clinical trial evidence than TB-500?

Neither peptide has completed human clinical trials published in the mainstream literature. BPC-157 has a larger base of older animal studies, particularly for gut and tendon models, while TB-500's most rigorous recent evidence is a 2024 rat metabolite and in-vitro wound-healing study. Both remain preclinical-stage evidence overall.

What would count as real proof TB-500 works for tendon or muscle injuries?

A registered trial (with a ClinicalTrials.gov number or equivalent), a placebo or comparator control group, diagnosed human injury patients, a pre-specified outcome measure like imaging-confirmed healing or return-to-play time, and peer-reviewed published results. No current TB-500 paper meets all of these criteria.

Why is TB-500 sold as a blend with BPC-157 instead of alone?

Because the compounding pharmacy pathway that legally supplies these peptides in the US, under 21 U.S.C. 353a, currently offers them combined rather than as a standalone TB-500 preparation. There is no legitimate standalone TB-500 SKU on the market through licensed provider channels.

Do the 2026 orthopaedic review papers on peptides prove TB-500 works?

No. The 2026 papers in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, The American Journal of Sports Medicine, and Sports Medicine (Auckland) are reviews discussing peptide therapies as an emerging clinical category, including safety and efficacy questions. They are not new clinical trials proving TB-500 specifically works.

Can TB-500 be detected in a drug test?

Yes. Analytical chemists have built specific liquid chromatography-mass spectrometry methods to detect TB-500 in human urine, equine urine and plasma, and blood, dating back to at least 2012. Multiple papers describe extraction, adsorption, and metabolite-detection methods developed specifically for anti-doping labs.

Sources

1. The American Journal of Sports Medicine, 2026 (PMID 41476424): A 2026 primer covers injectable peptide therapy as an emerging category for orthopaedic and sports medicine physicians
2. Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, 2026 (PMID 41490200): A 2026 review covers applications, challenges, and future directions of therapeutic peptides in orthopaedics
3. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): A 2026 review examines safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
4. Drug Testing and Analysis, 2012 (PMID 22962027): Researchers synthesized and characterized the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in commercial TB-500 to confirm its chemical identity
5. Journal of Chromatography B, 2024 (PMID 38382158): A 2024 study quantified TB-500 and its metabolites in vitro and in rats and screened metabolites for wound-healing activity in vitro
6. Frontiers in Aging, 2026 (PMID 42021992): A 2026 review discusses mechanisms and applications of therapeutic peptides in gerontology for healthy aging
7. Journal of Chromatography A, 2012 (PMID 23084823): A 2012 method was developed to detect TB-500 in equine urine and plasma by LC-MS for doping control
8. Analytical and Bioanalytical Chemistry, 2013 (PMID 23318763): A 2013 method covers doping control analysis of seven bioactive peptides including TB-500 in horse plasma
9. Analytical Biochemistry, 2017 (PMID 28887173): A 2017 study examined adsorption effects for doping-relevant peptides including TB-500 during lab handling
10. Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): A 2014 review covers analytical approaches for detecting emerging therapeutics including TB-500 in human doping controls
11. Expert Review of Proteomics, 2014 (PMID 25382550): A 2014 review covers detection methods for peptidic drugs and drug candidates in sports doping
12. Journal of Peptide Science, 2015 (PMID 25469748): A 2015 paper developed in-vitro models for metabolic studies of small peptide hormones for sport drug testing
13. Journal of Separation Science, 2016 (PMID 26578461): A 2016 method simplified screening for peptides under 2 kDa via direct urine injection and ion mobility mass spectrometry
14. Journal of Proteomics, 2016 (PMID 27569051): A 2016 study compared in-vitro model systems for metabolizing synthetic doping peptides, including enzyme and microsome models
15. Drug Testing and Analysis, 2016 (PMID 26472487): A 2016 paper developed solid-phase extraction methods for small bioactive peptides from human urine
16. FDA, Drugs@FDA approved drug products database: TB-500 has no FDA-approved drug application listed in Drugs@FDA
17. 21 CFR 216.23, the 503A Bulks List: TB-500 is not listed on FDA's 503A bulk drug substances list for traditional compounding
18. 21 CFR 216.24, the 503B Bulks List: TB-500 is not listed on FDA's 503B bulk drug substances list for outsourcing facility compounding
19. FDA, Bulk drug substances nominated for use in compounding (current list): FDA maintains a current nomination list of bulk drug substances proposed for 503A compounding use
20. 21 U.S.C. 353a, pharmacy compounding statute: Pharmacy compounding of preparations like a BPC-157/TB-500 blend is governed by 21 U.S.C. 353a